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SuMMAry The AT motif binding factor 1 (ATBF1) is expressed in vari-
ous tissues, such as brain, liver, lung, and gastrointestinal tract, and has 
an important role in cell differentiation in organs. ATBF1 interacts with 
PIAS3, a protein inhibitor for activated signal transducer and activator 
of transcription (STAT3), to suppress STAT3 signaling, which has critical 
roles in cell proliferation, migration, and survival. We hypothesized that 
ATBF1 is a useful prognostic marker for skin cancer. We performed im-
munohistochemical analyses of squamous cell carcinoma (SCC, n=7), 
basal cell carcinoma (BCC, n=4), and Bowen’s disease (n=4) tissues us-
ing an anti-ATBF1 monoclonal antibody. All cases of BCC and Bowen’s 
disease exhibited intense nuclear ATBF1 staining, whereas only some 
SCC cases exhibited weakly positive nuclear ATBF1 staining. SCC and 
Bowen’s disease showed intense nuclear STAT3 staining, while BCC had 
few STAT3-positive nuclei. Based on these observations, nuclear ATBF1 
staining was associated with low malignancy profiles. The pattern of 
ATBF1 staining is a potential prognostic marker for skin cancer. 
Key wordS: ATBF 1, basal cell carcinoma, Bowen’s disease, squamous 
cell carcinoma
INTroduCTIoN
The AT motif binding factor 1 (ATBF1, also known 
as ZFHX3), which is expressed in various tissues, such 
as brain, liver, lung, and gastrointestinal tract, has an 
important role in cell differentiation (1-4). The ATBF1 
complementary DNA was originally isolated from hu-
man hepatoma cells based on the ability of its prod-
uct to bind to an AT-rich element in the enhancer of 
the human α-fetoprotein (AFP) gene (4). The gene is 
located at chromosome 16q22.3-q23.1, which shows 
a loss of heterozygosity in various malignant tumors 
(5-7). ATBF1 mRNA is abundant in normal prostate, 
but scarce in approximately half of the prostate can-
cers tested (8). In 24 of 66 (36%) prostate cancers ex-
amined, 22 unique somatic mutations, many of which 
impair ATBF1 function, were detected (8). ATBF1 in-
hibits cell proliferation, thus the loss of ATBF1 func-
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tion might be a mechanism through which growth 
control is lost in prostate cancer (8).
Full-length ATBF1 complementary DNA, contain-
ing 23 zinc finger motifs, was isolated in 1995 (9). It 
is referred to as ATBF1-A (404-kDa, 4 homeodomains, 
and 23 zinc finger motifs) and is 3.3 kb longer than the 
previously reported clone, now identified as ATBF1-B 
(306 kDa, 4 homeodomains, and 17 zinc finger mo-
tifs). ATBF1-A suppresses AFP gene expression. The 
absence of ATBF1-A is a distinct feature of AFP-pro-
ducing gastric cancer cells, which are characterized 
by extremely high malignancy (3). In 81 sporadic gas-
tric cancers, loss of heterozygosity at the ATBF1 locus 
was detected in 52.9% of informative samples (10). In 
breast cancer, levels of ATBF1-A mRNA might serve as 
a predictive indicator of lymph node metastasis be-
cause a higher level of ATBF1-A is related to a better 
prognosis. Therefore, ATBF1-A gene expression might 
be a marker of endocrine responsiveness and a prog-
nostic indicator for breast cancer progression (11). In 
breast cancer cells, estrogen receptor signaling pro-
motes cell growth and proliferation. ATBF-1 inhibits 
estrogen receptor function by competing with the 
steroid receptor coactivator AIB1 to bind to the es-
trogen receptor in estrogen receptor-positive breast 
cancer cells. These findings provide an underlying 
mechanism for the suppression of breast cancer cell 
proliferation by ATBF1 (12). 
Based on the studies using a yeast two-hybrid sys-
tem, Nojiri et al. report that ATBF1 was a negative reg-
ulatory factor for signal transducer and activator of 
transcription (STAT)3-mediated signal transduction 
through its interaction with PIAS3, an activated STAT3 
protein inhibitor (13). STAT3 is an important transcrip-
tion factor for the development of psoriasis and skin 
cancers under some conditions (14,15). We hypoth-
esized that ATBF1 expression is related to pathologic 
differences among skin cancers. Therefore, in the 
present study we investigated the staining patterns 
and intensity of ATBF1 and STAT3 in squamous cell 
carcinoma (SCC), Bowen’s disease, and basal cell car-
cinoma (BCC) using specific monoclonal antibodies. 
MATerIAlS ANd MeThodS
Patients and tumor samples 
Fifteen skin carcinoma tissues from SCC (n= 7), 
BCC (n = 4), and Bowen’s disease (Bowen, n=4) were 
used in this study. All tissues were obtained by exci-
sion or biopsy from 12 patients (10 men and 2 wom-
en; 7 SCC, 4 BCC, and 4 Bowen patients, including 2 
cases of double or triple cancer) at the Dermatology 
Clinic, Nagoya Midori Municipal Hospital, Nagoya, 
Japan, from April 2004 to March 2008. A written in-
formed consent was obtained from all patients under 
institutional approval. 
Immunohistochemical staining of ATBF1-
A protein 
R87-5 rat monoclonal IgG anti-human ATBF1-A 
antibody (MBL, Nagoya, Japan) and an Ultrateck HRP 
(DAB) Streptavidin-Biotin Detection System (Beck-
man Coulter, Marseille, France) were used. Anti-hu-
man ATBF1-A antibody was diluted 4000 times (0.68 
μg/mL). Tissue sections were deparaffinized and re-
hydrated. All sections were treated with 3% hydro-
gen peroxide in water to block endogenous peroxi-
dase activity, and a protein-blocking agent (Beckman 
Coulter) was used. The slides were incubated with 
anti-human ATBF1-A antibody for 60 min at room 
temperature. Immunoreactive products were detect-
ed using the streptavidin-biotin system according to 
the manufacturer’s instructions, then visualized after 
adding 3,3’-diaminobenzidine (DAB) as the chromo-
gen. Tissue sections were counterstained with hema-
toxylin.
Immunohistochemical staining of STAT-3 
and proliferating cell nuclear antigen
Mouse monoclonal IgG anti-human STAT-3 an-
tibody (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA), mouse monoclonal IgG anti-human prolifer-
ating cell nuclear antigen (PCNA; clone PC10, Dako 
Cytomation, Glostrup, Denmark), a Histofine SAB-PO 
kit (Nitirei Bioscience, Tokyo, Japan), and DAB (Dako 
Japan, Kyoto, Japan) were used. Anti-human STAT-
3 antibody was diluted 100 times (2.00 µg/mL) and 
anti-human PCNA antibody was diluted 400 times 
(1.31 µg/mL). Tissue sections were deparaffinized 
and rehydrated and boiled in citrate-buffered saline 
(pH=6.0; Mitsubishi Kagaku Yatoron, Tokyo, Japan) to 
improve staining. All sections were treated for 30 min 
with methanol containing 3% hydrogen peroxide 
to block endogenous peroxidase activity, and 10% 
goat serum to block proteins. The slides were incu-
bated with anti-human STAT-3 antibody or anti-hu-
man PCNA antibody for 60 min at room temperature. 
Immunoreactive products were detected using the 
streptavidin-biotin system according to the manu-
facturer’s instructions, then visualized using DAB as 
the chromogen. Tissue sections were counterstained 
with hematoxylin. 
Evaluation of staining intensity
Staining was observed under an Olympus AX80T 
microscope (Olympus, Tokyo, Japan) and an Olympus 
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DP70 color video camera (Olympus, Tokyo, Japan). Im-
munoreactivity of over 50% of the tumor lesion was de-
fined as positive (+). Immunoreactivity of less than 50% 
was defined as indeterminate (±). A complete lack of im-
munoreactivity was defined as negative (-). Immunore-
activity was classified as nuclear, cytoplasmic, or both. 
reSulTS
ATBF1 staining patterns, i.e., nuclear and cyto-
plasmic, and intensity were analyzed in BCC, Bowen’s 
disease, and SCC. Representative staining patterns 
of BCC, Bowen’s disease, and SCC are shown in Fig-
ure 1. In BCC, we observed intense nuclear staining 
of ATBF1, but no STAT3 staining. In Bowen’s disease, 
we observed nuclear and cytoplasmic staining of 
ATBF1. The cytoplasmic staining was weaker than the 
nuclear staining. Nuclear STAT3 staining was also ob-
served. In SCC, we observed cytoplasmic staining of 
ATBF1 and strong nuclear staining of STAT3, as previ-
ously reported (14,15). The nuclear staining of ATBF1 
occurred in low malignancy cancers such as BCC and 
Bowen’s disease. 
The staining patterns in all tested samples are 
summarized in Table 1 and shown in Figure 2. All 
Figure 1. Representative ATBF1 and STAT3 staining patterns. Tissue sections 
of basal cell carcinoma (BCC), Bowen’s disease, and squamous cell carcinoma 
(SCC) were stained with anti-human ATBF1-A antibody and anti-human STAT-
3 antibody. Immunoreactive products were detected using the streptavidin-
biotin system and visualized with DAB. Bar indicates 50 µm. Intensive nuclear 
staining of ATBF1 was observed in BCC and Bowen’s disease, but not in SCC. 
STAT3 staining was not observed in BCC, but was observed in Bowen’s disease. 
In SCC, cytoplasmic staining of ATBF1 was observed and nuclear STAT3 stain-
ing was profound.
Nishio et al. Acta Dermatovenerol Croat
Nuclear translocation of ATBF 1 2012;20(4):239-245
242 ACTA DERMATOVENEROLOGICA CROATICA
4 cases of BCC and all 4 cases of Bowen’s disease 
showed nuclear ATBF1 staining (Fig. 2A, 2B). The 
Bowen’s disease samples also had weak cytoplasmic 
ATBF1 staining. In contrast, 6 of 7 SCC cases showed 
cytoplasmic ATBF1 staining, and 5 of 7 SCC cases had 
weakly positive nuclear ATBF1 staining (Fig. 2C). In 
other cases (2 of 7 SCC), ATBF1 staining was similar 
to that of Bowen’s disease, with both nuclear and 
cytoplasmic staining (Fig. 2C, bottom). Normal skin 
showed no nuclear ATBF1 staining, but cytoplasmic 
staining was observed (data not shown).
The 4 BCC cases had no STAT3-positive nuclei 
(Fig. 2A). Among the 4 Bowen’s disease cases, 3 had 
nuclear STAT3 staining (Fig. 2B). The SCC cases had in-
tense STAT3 nuclear staining, especially at the grow-
ing edges of the tumor (Fig. 2C). Almost all of the BCC, 
SCC, and Bowen’s disease tumors were positive for 
anti-PCNA (Fig. 2A, B, C).  
These observations suggest that nuclear ATBF1 
staining is associated with low malignancy profiles.  
dISCuSSIoN
Intense nuclear ATBF1 staining was observed in 
all cases of BCC and Bowen’s disease, whereas only 
weakly positive nuclear ATBF1 staining was observed 
in some SCC cases. In contrast, intense STAT3 nuclear 
staining was observed in SCC, especially at the grow-
ing edges of the tumor, while few STAT3-positive nu-
clei were observed in BCC. These findings indicate 
that ATBF1 is a potential prognostic marker for skin 
cancer. In particular, nuclear staining of ATBF1 indi-
cates low biologic malignancy. 
Liu et al. (15) report STAT3 activation via p-STAT3 
nuclear translocation in cutaneous SCC. In their study, 
cytoplasmic distribution and nuclear translocation of 
STAT3 were observed in either normal (62.5%; 5/8) 
tissues or tissues with various neoplastic changes. In 
normal epidermis, only the cells located in the basal 
layer were p-STAT3 positive, whereas p-STAT3 positive 
cells were distributed diffusely in the tumor tissue, es-
pecially in SCC. Because normal basal cells continu-
ously regenerate to replace aged epithelial cells and 
Table 1. ATBF1, STAT3, and PCNA staining in different skin cancer groups






BCC1 - + - +
BCC2 ± + - +
BCC3 ± + - +
BCC4 - + - +
SCC1 - ± + +
SCC2 + ± + +
SCC3 + + + +
SCC4 + ± + +
SCC5 + ± + +
SCC6 + ± + +
SCC7 ± + + +
Bowen1 ± + + +
Bowen2 ± + - +
Bowen3 ± + + +
Bowen4 ± + + +
+ = staining over 50%
± = staining under 50%
- = non staining
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Figure 2. Immunohistochemical staining of ATBF1, STAT3, and PCNA: (A) basal cell carcinoma (BCC); (B) Bowen’s disease; (C) 
squamous cell carcinoma (SCC). All test samples are shown except for 4 of 7 SCC. The case number corresponds to the case 
number in Table 1. The bar in the lower magnification panels indicates 500 µm and that in the higher magnification panels 
indicates 100 µm for the STAT3 and PCNA panels and 50 µm for the ATBF1 panel. In BCC (A), the staining pattern was similar 
in all cases. Intensive nuclear staining of ATBF1 was observed in all 4 cases of BCC. No STAT3-positive nuclei were observed 
in any of the 4 BCC cases. In Bowen’s disease (B), intensive nuclear staining of ATBF1 was observed in all cases. STAT3 nuclear 
staining was observed in 3 of the 4 cases of Bowen’s disease. In SCC (C), cytoplasmic staining was observed in 6 of 7 SCC 
cases (#3, #4, #7 in this figure), whereas positive nuclear ATBF1 staining was observed in 5 of 7 SCC cases (#1, #3, #4, #7 in this 
figure). STAT3 nuclear staining was observed in all cases.
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STAT3 is required for the survival and proliferation of 
skin cancers, restricted amounts of p-STAT3 in regen-
erative normal basal cells and diffuse p-STAT3 in epi-
dermal cancer tissues are not unexpected findings.
ATBF1 is highly expressed in psoriatic skin lesions, 
especially in the squamous to granular layers, but not 
in the basal layer (unpublished data). STAT3 is strong-
ly expressed in the cytoplasm in the basal layer and 
expression gradually decreases in the squamous lay-
er, but, like ATBF1, the activated form is found in the 
nucleus. Thus, the ATBF1 expression pattern indicates 
that STAT3 activation is suppressed in psoriatic skin 
lesions. Nuclear ATBF1 staining was observed in BCC 
and Bowen’s disease, whereas only weak ATBF1 nu-
clear staining was observed in some SCC. In contrast, 
nuclear STAT3 staining was observed in SCC. These 
findings indicate that ATBF1 expression suppresses 
STAT3 activation in BCC and Bowen’s disease, and is 
associated with low malignancy profiles.  
Heat shock proteins (HSP) have also been analyzed 
as skin cancer markers. Western blot and immunohis-
tochemical staining studies revealed overexpression of 
HSP105 in extramammary Paget disease and SCC, and 
minimal expression in BCC (16). Immunohistochem-
istry analysis indicated that 56% of extramammary 
Paget disease, 60% of primary SCC, and 100% of meta-
static SCC highly expressed HSP105, while only 13% of 
BCC lesions showed increased HSP105 expression.
HSP27 is member of the small HSP family. In a pre-
vious study of 10 BCC, 6 SCC, and 8 Bowen’s disease, 
the HSP27 expression pattern was similar in all of the 
specimens tested (17). In solid BCC, there was no dif-
ference in the HSP27 expression pattern between the 
peripheral and central cells of the tumor mass. In dif-
ferentiating BCC, however, positively staining cells in 
the central parts of the tumor were observed. In SCC 
tumors, HSP27 was weakly expressed or undetect-
able. A low level of HSP27 expression was detected 
in the more highly differentiated parts. No immu-
noreactivity was detected in the areas of invasion. 
In Bowen’s disease, HSP27 was detected in the up-
per cell layers in the areas of lesions, where normal 
stratification seems to be conserved. Atypical cells of 
Bowen’s disease did not express HSP27, and infiltrat-
ing cells in carcinoma arising from Bowen’s disease 
were negative.
CoNCluSIoN
Based on the findings of the present study, ATBF1 
is a potential prognostic marker for skin cancer. Fur-
ther studies are necessary, however, to examine the 
relation of ATBF1 with other factors, including tumor 
stage and size, and clinical prognosis.  
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